Perrigo Company plc - Form 8-K Summary
Business Context and Reporting Period
Perrigo Company plc (PRGO), an Ireland-based pharmaceutical company, filed this Current Report on Form 8-K on April 30, 2020. The filing announces the release of earnings results for the first quarter ended March 28, 2020. The detailed financial data is contained in the attached press release (Exhibit 99.1), which is not included in the text of this filing.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references the release of these results but does not list the figures within the 8-K document itself.
Material Changes and Adjustments
The Company provides non-GAAP financial measures to facilitate comparability by excluding specific items. The filing details the adjustments made for the three months ended March 28, 2020, and the comparable period in 2019:
- 2020 Adjustments: Amortization of acquired intangibles, changes in financial assets, gains/losses on investment securities, acquisition and integration charges, separation and reorganization expenses, unusual litigation, foreign currency translation, Ranir net sales, and non-GAAP tax adjustments.
- 2019 Adjustments: Similar items as 2020, plus impairment charges, restructuring charges, gains/losses on divestitures, and net sales from exited businesses (Animal Health and Canoderm prescription product).
The Company notes that non-GAAP measures exclude the impact of exited businesses and the 2019 acquisition of Ranir to show organic trends.
Guidance, Outlook, and Risks
This filing does not contain specific forward-looking guidance, updated outlook figures, or a detailed discussion of risks and contingencies beyond the standard disclosure regarding the use of non-GAAP measures. Management utilizes these adjusted measures for planning, forecasting, and compensation determinations.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2020 revenue, net income, and EPS figures.
- Verify the reconciliation between GAAP and non-GAAP financial measures to understand the impact of excluded items like amortization and restructuring.
- Assess the impact of the Ranir acquisition and exited businesses (Animal Health, Canoderm) on year-over-year comparisons.
- Confirm the status of "unusual litigation" and "separation and reorganization expenses" mentioned in the adjustments.